Colorectal Cancer | Specialty

Second-Line Therapy Options in mCRC

February 12th 2016

Considering Maintenance Therapy in mCRC

February 12th 2016

Optimizing Frontline Chemotherapy in mCRC

February 12th 2016

FOLFOX versus FOLFIRI in the MAVERICC Trial in CRC

February 12th 2016

Systemic Therapy Approaches in mCRC

February 12th 2016

Immunotherapy and MSI Status in Colorectal Cancer

February 12th 2016

Molecular Profiling in Colorectal Cancer

February 12th 2016

Liver-Directed Therapies in Metastatic Colorectal Cancer

February 12th 2016

Metastatic Colorectal Cancer: Goals of Resection

February 12th 2016

Taking a Multidisciplinary Approach to mCRC Care

February 12th 2016

Patient Populations Provide Sequencing Clues in Chemorefractory CRC

February 11th 2016

Treating patients with chemorefractory advanced colorectal cancer has undergone a significant transformation in recent years. Now, with two agents approved, the optimal sequence for therapies regorafenib and TAS-102 becomes the next relevant question.

PFS in Metastatic Colorectal Cancer Similar with Two Chemo Backbones

January 26th 2016

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.

Dr. Melis on Avoiding Surgery for Patients With Rectal Cancer

January 26th 2016

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

Three Drugs Marginally Better Than Two in First-Line Metastatic Colorectal Cancer

January 25th 2016

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

Panitumumab Improves Survival in Chemorefractory mCRC

January 25th 2016

Adding panitumumab (Vectibix) to best supportive care reduced the risk of death by 30% for patients with RAS wild-type chemorefractory metastatic colorectal cancer.

Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC

January 22nd 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.

New Neoadjuvant Regimen Shows Similar Efficacy, Less Toxicity in Rectal Cancer

January 19th 2016

Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.

NYU Expert Examines Emerging Agents in Colorectal Cancer

December 31st 2015

Jennifer Wu, MD, sheds light on TAS-102, as well as some emerging agents likely to play a role in the treatment of patients with colorectal cancer.

Expert Discusses Future of Treatment in CRC

December 30th 2015

John L. Marshall, MD, discusses treatment advancements and other ongoing developments in colorectal cancer.

Dr. Wiesner on Importance of Genetic Testing for CRC

December 28th 2015

Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the importance of genetic testing for colorectal cancer.